Compare BDC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDC | LEGN |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 1994 | 2020 |
| Metric | BDC | LEGN |
|---|---|---|
| Price | $117.55 | $17.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $148.33 | $63.08 |
| AVG Volume (30 Days) | 305.8K | ★ 1.5M |
| Earning Date | 04-30-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 23.13 | N/A |
| EPS | ★ 5.91 | N/A |
| Revenue | ★ $2,715,194,000.00 | N/A |
| Revenue This Year | $8.91 | $46.27 |
| Revenue Next Year | $4.70 | $28.77 |
| P/E Ratio | $18.92 | ★ N/A |
| Revenue Growth | ★ 10.33 | N/A |
| 52 Week Low | $83.18 | $16.24 |
| 52 Week High | $159.99 | $45.30 |
| Indicator | BDC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 38.56 |
| Support Level | $113.99 | $16.24 |
| Resistance Level | $125.01 | $20.39 |
| Average True Range (ATR) | 4.37 | 0.80 |
| MACD | -1.60 | -0.14 |
| Stochastic Oscillator | 23.97 | 5.42 |
Belden Inc is a supplier of complete connection solutions. It has two segments, Smart Infrastructure Solutions and Automation Solutions. Smart Infrastructure Solutions provides network infrastructure and broadband solutions, serving markets such as data centers, government, healthcare, and broadband and wireless service providers, with products including copper and fiber cable and connectivity solutions. Automation Solutions provides digitization and automation solutions that enable IT OT convergence and support acquisition, transmission, orchestration, and management, serving markets including Warehousing and Logistics, Energy, Transportation, and Discrete Manufacturing. The company operates in the Americas, EMEA, and APAC, with maximum revenue coming from the Americas.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.